A Karim Kader
Overview
Explore the profile of A Karim Kader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1701
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roberts J, Wang L, Rose B, Seibert T, Madlensky L, Nielsen S, et al.
Urol Oncol
. 2024 Oct;
43(3):195.e21-195.e27.
PMID: 39482144
Purpose: The availability of targeted therapies for advanced prostate cancer led to the expansion of national guidelines recommending germline genetic testing. The aim of this study was to describe recent...
2.
Bryant A, Nelson T, McKay R, Kader A, Parsons J, Einck J, et al.
BJUI Compass
. 2022 May;
3(3):243-250.
PMID: 35492227
Objective: To analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer (PCa) treated with radiation therapy. Subjects And Methods: We identified 12 784 patients with...
3.
Javier-Desloges J, Nelson T, Murphy J, McKay R, Stewart T, Kader A, et al.
Urol Oncol
. 2022 Apr;
40(5):199.e15-199.e21.
PMID: 35431133
Objectives: To determine the representation of women, minorities, and the elderly groups in clinical trials and whether participation has changed over time. Methods: Retrospective study in the National Cancer Institute...
4.
Courtney P, Deka R, Kotha N, Cherry D, Salans M, Nelson T, et al.
J Natl Compr Canc Netw
. 2022 Feb;
20(2):151-159.
PMID: 35130495
Background: Active surveillance (AS) is a safe treatment option for men with low-risk, localized prostate cancer. However, the safety of AS for patients with intermediate-risk prostate cancer remains unclear. Patients...
5.
Kotha N, Kumar A, Qiao E, Qian A, Voora R, Nalawade V, et al.
J Natl Cancer Inst
. 2021 Dec;
114(4):600-608.
PMID: 34918091
Background: African American patients with bladder cancer have inferior outcomes compared with non-Hispanic White (White) patients. We hypothesize that access to health care is a primary determinant of this disparity....
6.
Javier-Desloges J, Nelson T, Murphy J, McKay R, Pan E, Parsons J, et al.
Cancer
. 2021 Nov;
128(4):770-777.
PMID: 34806168
Background: This study was done to determine the representation of minorities, women, and the elderly in National Cancer Institute (NCI) clinical trials. Methods: This is an analysis in the NCI...
7.
Courtney P, Deka R, Kotha N, Cherry D, Salans M, Nelson T, et al.
Cancer
. 2021 Aug;
127(23):4403-4412.
PMID: 34347291
Background: The safety of active surveillance (AS) for African American men compared with non-Hispanic White (White) men with intermediate-risk prostate cancer is unclear. Methods: The authors identified patients with modified...
8.
Kumar A, Cherry D, Courtney P, Nalawade V, Kotha N, Riviere P, et al.
Eur Urol Open Sci
. 2021 Aug;
30:1-10.
PMID: 34337540
Background: Muscle-invasive bladder cancer (MIBC) remains undertreated despite multiple potentially curative options. Both radical cystectomy (RC) with or without neoadjuvant chemotherapy and trimodal therapy (TMT), including transurethral resection of bladder...
9.
Hendrix N, Gulati R, Jiao B, Kader A, Ryan S, Etzioni R
Am J Epidemiol
. 2021 May;
190(10):2064-2074.
PMID: 34023874
Cancer risk prediction is necessary for precision early detection, which matches screening intensity to risk. However, practical steps for translating risk predictions to risk-stratified screening policies are not well established....
10.
Gaylis F, Bree K, Dato P, Andriole G, Kane C, Kader A
Rev Urol
. 2021 Apr;
22(4):152-158.
PMID: 33927572
Broad-based prostate-specific antigen (PSA) screening has saved lives but at a substantial human and financial cost. One way of mitigating this harm, while maintaining and possibly improving the benefit, is...